ArticleInternational journal of hematology2025
Successful autologous stem cell transplantation in a case of central nervous system relapse of diffuse large B-cell lymphoma with concurrent polycythemia vera.
Article in International journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diffuse large B-cell lymphoma (DLBCL) with central nervous system (CNS) relapse is associated with a poor prognosis, and treatment becomes particularly challenging in such cases when complicated by polycythemia vera (PV). We report a unique case of CNS-relapsed DLBCL coexisting with PV, successfully treated with autologous stem cell transplantation (ASCT). A 64-year-old man achieved complete remission following R-CHOP therapy for DLBCL but developed isolated CNS relapse one year later. After achieving partial remission with high-dose methotrexate, he was referred for ASCT. On admission, erythrocytosis prompted further evaluation, leading to a diagnosis of JAK2 V617F-positive PV with an allele burden of 37.7%. Following phlebotomy, peripheral blood stem cells were successfully mobilized using reduced-dose G-CSF and plerixafor. ASCT was performed using a conditioning regimen of busulfan and thiotepa. Neutrophil engraftment occurred by day 10 without major adverse events. At 30 months post-ASCT, the patient remains in complete remission, with stable hemoglobin levels, a reduced JAK2 V617F allele burden (~ 12%), and no need for further phlebotomy. This case highlights the feasibility and potential dual therapeutic benefit of thiotepa-based ASCT in patients with coexisting CNS-relapsed DLBCL and PV. To our knowledge, this is the first reported case of ASCT in this clinical context.
Indexed as
Identifiers
40583082What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.